Analystreport

Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target raised by analysts at Wedbush from $6.00 to $7.00. They now have a "neutral" rating on the stock.

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806